Valproate (VPA, NSC-93819, valproic acid, sodium valproate, and divalproex sodium) is an approved medication mainly used for the treatment of epilepsy and bipolar disorder, also used to prevent migraine headaches.

PTACH (also known as NCH-51), a SAHA analog, is a novel and potent inhibitor of human histone deacetylase (HDAC).

Quisinostat (formerly JNJ26481585) is an orally bioavailable, 2nd generation, hydroxamate-based inhibitor of histone deacetylase (HDAC) with potential anticancer activity.

Santacruzamate A (also known as CAY10683) is a potent and selective inhibitor of HDAC (histone deacetylase) with IC50 of 119 pM for HDAC2, it exhibits >3600-fold selectivity over other HDACs.

AR-42 (HDAC-42, NSC-736012, OSU-42 etc.) is a novel and potent histone deacetylase (HDAC) inhibitor with potential antitumor activity.

HPOB is a novel, potent and selective inhibitor of histone deacetylase 6 (HDAC6) inhibitor with potential anticancer activity.

RGFP966 (RGF-P966) is a novel, potent and highly selective inhibitor of HDAC3 (histone deacetylase 3) with potential anticancer activity.

Panobinostat (formerly known as LBH-589 and NVP LBH-589; trade name Farydak) is a novel, potent and broad-spectrum/non-selective/pan-HDAC inhibitor with potential anticancer activity.

Givinostat (formerly ITF2357; Gavinostat) is a potent and orally bioavailable inhibitor of both class I and class II histone deacetylase (HDAC) with potential anticancer activity.

Nexturastat A (AG-CR1-3901), an aryl urea analog, is a novel, potent and selective inhibitor of histone deacetylase 6 (HDAC6) with potential anticancer activity.